LivaNova (NASDAQ:LIVN - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 3.600-3.700 for the period, compared to the consensus EPS estimate of 3.580. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.
LivaNova Stock Down 3.3 %
Shares of LIVN stock opened at $35.10 on Wednesday. LivaNova has a 1-year low of $32.48 and a 1-year high of $64.07. The company has a market cap of $1.91 billion, a price-to-earnings ratio of 83.57 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The stock's fifty day moving average price is $37.76 and its 200 day moving average price is $45.34.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on LIVN shares. Mizuho dropped their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, March 25th. Stifel Nicolaus cut their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group lowered their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research report on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, LivaNova has a consensus rating of "Buy" and an average target price of $61.17.
View Our Latest Research Report on LIVN
About LivaNova
(
Get Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
